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Abstract: The article presents critical analysis of current methodological approaches, the standard and the options of 
complex therapy of malignant brain tumors (MBT). Author defines the main reasons for low effectiveness of MBT 
therapy. Relying on post-genome innovations (mass-spectrometry proteome mapping and whole transcriptome profiling 
of gene expression of cancer cells (CCs), cancer stem cells (CSCs) and tissue-specific stem cells (TSSCs) of the cancer 
patient, and their comparative analysis) the author proposes systemic solution for the MBT complex therapy that consists 
in a new alternative paradigm of cytoregulatory anti-cancer treatment of the MBT that is aimed at rigid control, 
management and regulation of the number of CCs and CSCs in the body. The goal of a new treatment paradigm is to 
transfer acute, uncontrollable and mortal process into chronic and non-lethal disease, and, thus, to improve survival 
rates and life quality of the patients. The instrument to implement the new paradigm is a sparing algorithm of 
conventional therapeutic methods and immune therapy, supplemented with personalized anti-tumor proteome-based cell 
therapy. The therapy implies transfusions of transcriptome-modified autologous TSSCs with specified properties to 
regulate the reproductive functions of the CSCs. The author proposes the complex therapy of the MBT and shows its 
social and economic significance for the society and neuroscience.  
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INTRODUCTION 
Cancer and other malignant tumors are aggressive 
severe somatic diseases that can injure any organs 
and tissues; they rate the second as the leading cause 
of deaths and primary disability of adult population [1]. 
According to IARC data 14 million of new cases of 
cancer are registered every year and 8.2 million of 
people die from cancer annually [2]. 
According to the American Society of Clinical 
Oncology, timely and correct therapy of cancer and 
malignant tumors increased 5 year survival of the 
patients by 14-19% and reduced mortality caused by 
cancer by 30%, due to the introduction of the 
therapeutic programs of early administration of new 
anti-cancer pharmaceuticals [3]. This significant 
achievement in the oncology is induced by the clinical 
application of the new generation of targeted anti-
cancer drugs. The innovation is underlain by the 
fundamental advances of contemporary biology of 
cancer based on the genome analysis, whole 
transcriptome analysis of gene expression of cancer 
cells (CCs) and cancer stem cells (CSCs) [4-6], and on 
the oncoproteomic mapping and profiling of CCs and  
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CSCs [7, 8]. Detection of a range of new oncospecific 
proteins in genome and post-genome assays allowed 
to determine new targets for the targeted therapies of 
cancer and to develop a whole series of innovative 
anti-cancer target drugs that specifically eliminate CCs 
and part of CSCs [9-12]. 
However, the expected results still has not been 
achieved [13-15]. Available genome and post-genome 
approaches of targeted anti-cancer therapy proved 
effective in the general oncology, but displayed low 
effectiveness in the therapy of malignant brain tumors 
(MBT). The diagnosis of MBT, as well as the 
metastases of cancer to the brain, remains the death 
sentence with no right for mercy. The median survival 
time of the cases of glioblastoma multiforme (GBM) 
varies from 12 to 15 months [11, 16, 17], and in the 
cases of the metastases of lung and breast cancer, the 
median survival time does not exceed 6-8 months [18]. 
Despite obvious progress in medicine in general, and in 
oncology in particular, these indicants remain stable for 
the last hundred years and do not depend on the scope 
of the accumulated evidence, or on the current achi- 
evements of cancer therapy with novel drugs [19, 20].  
We believe that the time has come to revise the 
dominating ideas and concepts of the MBT treatment 
and to set the benchmarks for further research. It is 
necessary to determine the fundamental reasons for 
2    World Journal of Oncology Research, 2016, Vol. 3 Bryukhovetskiy and Bryukhovetskiy 
the failures and systemic errors of the MBT therapy 
and to critically evaluate the challenges. Obviously, the 
paradigm of the MBT treatment has outdated, and we 
have to develop a new alternative paradigm of the MBT 
treatment. 
THE STATE OF ART AND AVAILABLE OPTIONS OF 
THE MBT TREATMENT 
 Critical analysis of the state of art in the MBT 
therapy and our own clinical practice showed that the 
efficacy of the MBT treatment is extremely low [19, 20]. 
Although active complex therapy does not 
guarantee maximal duration of life, the quality of life 
can be improved in many cases. The survival rate of 
the cases of slowly growing differentiated gliomas 
varies from 32 to 68% (5 years) and from 19 to 39% 
(10 years). For rapidly growing anaplastic 
astrocytomas, one year survival rate is shown by 
85.5% cases, two years survival by 70.9% and three 
years survival by 27.3%. In glioblastoma, the 68.1% 
cases survive up to one year, 23.7% up to two years 
and 4.3% up to 3 years [14, 16, 19, 21, 22]. 
The truth behind these achievements is that there is 
no protocol, no pharmaceutical or biotechnology that 
can provide at least two-year survival to glioblastoma 
patients. Obviously, the regular army of 
neuroncologists, oncogeneticists, and molecular 
biologists is not able to cope with the MBT. It is the 
time to face the truth and to acknowledge that 
contemporary neurooncology arrived to the scientific 
dead end in their search for effective therapy of MBT.  
THE REASONS FOR THE FAILURES IN THE MBT 
THERAPY AND POSSIBLE WAYS OUT OF THE 
CRISIS IN NEUROONCOLOGY 
Our theoretical analysis of the state of the affairs in 
the MBT treatment showed that the main reasons for 
its ineffectiveness lie in the erroneous scientific 
methodology and absence of scientifically grounded 
theoretical concept of contemporary therapy of these 
diseases, and not in the lack of the fundamental 
molecular-biological and applied clinical knowledge. 
The evidence gathered in the sphere of molecular 
biology of cancer and MBT are multi-faceted and 
fundamental and are sufficient to develop effective 
medical technology [23-27]. Meanwhile, the formal 
barriers, standardized therapeutic dogmas and 
organizational prejudices are so systemic and huge 
that resist any alternative considerations of the 
methodology of the treatment of these neoplasms.  
We think that one of the key reasons for the regular 
failures in the MBT therapy is that the neurooncologists 
became the hostages of the standards, regulations and 
guidelines of contemporary neurosurgery and 
neurooncology. The neurosurgeons walked away from 
the dogmas of general oncology and elaborated their 
own, a so-called “neurosurgical oncology” that focused 
on the development of neuronavigation and stereotaxic 
diagnostics and treatment of the MBT [14, 28]. 
Obsession with computer innovations led to the 
development of many stereotaxic radiosurgical and X-
ray complexes, but we forget that the surgery in 
oncology is the demonstration of weakness in the 
science and misunderstanding of the basics of the 
biology of the MBT development [29-32]. We do not 
want to reduce the importance of surgical methods in 
oncology, but insist that the role of the surgery must be 
limited to the maximal primary (and rarely repeated) 
excision of the tumor mass in the brain, isolation of the 
biological material for diagnostics and production of 
individual preparation for the MBT therapy.  
The standards recommended by the Association of 
Neurosurgeons in Russia [33] comply with the 
standards of the World Association of Neurosurgical 
Societies and are similar around the world, although 
they do not take into account the frontiers of genome 
and post-genome research of the MBT. The 
neurooncologist is trapped by the standards and 
options that were established in the beginning and end 
of the 20th century and is not able to think different.  
The standards mostly concern about the 
neurosurgical care to the MBT patients. Contemporary 
“Standards and Options…” provide for a very 
convenient clinical position and legal form to excuse 
low effectiveness of the MBT therapy and high mortality 
rates.  
Usually, at the first stage of the standard cancer 
therapy (surgery, chemo- and radiotherapy) and 
symptomatic administration of high doses of 
glucocorticoid hormones and antiedemics lead to the 
vigorous clinical restoration, stabilization of the 
patient’s condition, reduction of the neurological deficit, 
and a clear image that seems to confirm total 
elimination of the tumor in the brain. This phenomenon 
is easy to verify by MRI, PET and CT [34, 35]. The 
patient is discharged as the cured. However, it is well 
known that it is physically and technically impossible to 
eliminate the glial MBT in a surgical way. The 
phenomenon can be illustrated by the phase-contrast 
image of the experimental glial tumor (Figure 1) that 
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demonstrates why surgery is unable to remove the 
whole tumor. The surgeon can remove only a visible 
part of the tumor. None of contemporary fluorescent 
dyes and nano-surgery [36] is able to visualize all 
existing focuses of perivascular growth of CCs. The 
effect of visual absence of the tumor in the brain and 
the consequent courses of chemo- and radiotherapy at 
the first stage of the therapy speak of allegedly real, 
although temporal, victory over the tumor. This therapy 
exhausts the patient’s organism and conceals 
adaptation of the CCs to newly established aggressive 
environment. 
 
Figure 1: Phase-contrast imaging of glioma. Arrows point to 
the areas of perivascular invasion.  
The first stage of “The standards and options…” 
almost completely depletes the resources of the 
available anti-cancer therapy of the MBT. The 
remission follows the first stage. The relapse is 
manifested in the repeated debut of neurologic deficit 
and continued tumor growth that in 95% of the cases 
are observed in 1-6 months in the bed of the removed 
tumor and two months post removal of the metastases 
in the brain [14]. Recurrent tumor requires repeated 
course of the complex anti-tumor therapy while the 
opportunity to provide real care to these patients is 
almost completely absent. 
Therefore, the existing therapeutic universal 
standard, guidelines and options are ineffective and 
useless. Still, there is no choice and any alternative 
approaches are rejected by the global community of 
the oncologists and neurosurgeons. Another tragic 
feature of this standard should be noted: the concept of 
contemporary standard therapy does not imply the 
opportunity of high quality of life, even if the patient 
survives. In the case of MBT, the patient is destined to 
have dementia even if they are lucky to survive the 
therapy. Fifty gray of the recommended broad-field or 
local radiation of the brain for 3 to 5 years leads to 
chronic radiation sickness and rapid development of 
the brain cortex degeneration and, finally, to total 
dementia. 
If we consider chemotherapeutic agents, massive 
chemotherapy with the inducers of apoptosis and other 
cytotoxic agents in therapeutic doses damages the 
brain, and it cannot be restored by available methods. 
The results of chemotherapeutic inducers of apoptosis 
are demonstrative (Figure 2). Therefore, even 
theoretically, in the case of positive outcome, the 
patient with treated MBT faces the severe psycho-
neurological disability with consequent progressing 
dementia and complete failure in social and family 
endeavor.  
The available standard of the MBT therapy is the 
logical consequence of a ubiquitously acknowledged 
paradigm of contemporary anti-cancer treatment. It 
aims at complete elimination of all CCs in the body until 
complete cure. Ideologically and theoretically, this 
standard of anti-cancer treatment has only one goal, 
and, namely, total elimination of all CCs in the body in 
any possible way, and this is the fundamental 
methodological error. 
Around the world, the neurooncology demands 
more and more new and potent chemotherapy drugs 
and novel equipment for radiation, and the industry 
meets these demands. It is noteworthy, that all of the 
innovations fit into the outdated paradigm of the MBT 
treatment aiming at the elimination of the CCs. To date, 
the cytoreductive approach to the MBT treatment [36, 
37] was enriched by the technologies of the focused 
ultrasound ablation, photodynamic therapy, anti-cancer 
thermotherapy, stereotaxic radiosurgery using Gamma 
Knife or Cyber Knife systems, ultrafraction therapy and 
other [30, 31, 38]. The cytotoxic method is improved 
now by new target monoclonal technologies and 
personalized immune preparations [39], such as anti-
cancer vaccines, activated cytotoxic leucocytes etc. 
[40-42]. The cytotoxic approach provided a 
methodological basis to the development of new nano-
drugs [15, 37, 43, 44] and boron neutron capture 
therapy or proton radiation. The paradox of quality 
versus price does not bother anyone, as all medical 
industry and the Big Pharma live on it. 
Probably, if in the previous two hundred years the 
oncologists and neurosurgeons did not succeed in the 
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elimination of all cancer cells in the body of a patient, 
we should stop repeating our mistakes. Perhaps, we 
should eliminate only that part of the CCs that leads to 
severe cancer intoxication of the body, exhausts its 
adaptive resources and disorders the function of the 
organ, and other part can be “negotiated” and taken 
under control. 
We presume that the problem of the survival of the 
CCs and CSCs is much deeper. Low effectiveness of 
various chemotherapy drugs and technologies in the 
elimination of the CCs is conditioned by the evolution of 
the somatic cells and their unique ability to develop the 
forms of life that are similar to the spores of the plants 
that are able to survive the unfavorable conditions of 
the environment and microenvironment. 
There is other biological reason for the impossibility 
to totally eliminate the CCs in the body. Almost all 
leading experts in oncology came to the conclusion that 
cancer and other malignant tumors are a genetic 
disorder of the nucleus of a tissue specific stem cell 
(TSSC) [45]. As a result of the mutational effect of 
various factors of carcinogenesis on the tissue-specific 
CCs, the CSCs with specific tumor phenotype develop, 
and they are the progenitors of all CCs clones of this 
tumor [46, 47]. There exist two complementary 
hypotheses of the origin of the CSCs of MBT. One 
supposes that they derive from mature gliocytes or 
other somatic cells by the activation of key genes of 
epithelial-mesenchymal transition (Snail, Twist, Slug, 
ZEB1, ZEB2, Lef-1) [48]. The second considers the 
development of the CSCs from the neural stem and 
progenitor cells of subventricular zones of lateral 
ventricles, granular layer of dental gyrus or other 
germinative zones of a mature brain of a human [24, 
49]. Uniformity of key genes and epigenetic 
mechanisms that regulate life processes, commonality 
of immunocytochemical markers of cell surface 
(CD133+), identity of 63.5% proteins of proteomic 
profile [50] speak in favor of the hypothesis, according 
to which the CSCs of GBM come from neural SCs of 
the brain. Both types of SCs are capable for constant 
self-renewal, migration, high replication activity and 
multipotency [46, 51, 52].  
Obviously, no matter how the CSCs were formed, it 
is impossible to eliminate them as any other somatic 
cell. The CSCs, as healthy SCs, will adapt and evolve 
in the unfavorable conditions of the microenvironment.  
Our research [8, 53] of comparative proteome 
mapping and profiling of the normalized signal intensity 
of the CSCs in GBM of different lines (U251 and U87) 
and healthy NSCs showed that only 36.7% of total 
1162 proteins are species-specific in the CSCs, while 
other oncospecific proteins are characteristic to Homo 
Sapiens. Same was observed in comparative whole 
transcriptome analysis of the expression of 29000 
genes of neural SCs and CSCs (CD133+), isolated 
from GBM cell culture of U251 and U87 lines (Figure 
3). Hence, common regulatory signals of the 
microenvironment provide almost no effect on the CCs 
and CSCs, just as chemo- and radiotherapies. 
Meanwhile, the CCs lead to the irreversible mutations 
of normal regional SCs and healthy differentiated cells 
of the cancer patient. Therefore, an old methodological 
 
Figure 2: Morphometric analysis of glioma C6 volume after 
different treatments 
А. Seven days old C6 glioma. (HSC and NSC transplanta- 
tion). В. Control experimental glioma (no treatment). The 
volume of glioma is 220.3 ml. С. Experimental glioma after 
NSC (left) and HSC (right) implantation. Volume is 170.4ml; р 
< 0.05. D. Glioma after implantation of the transcriptome 
modified NSC (right) and HSC (left). Glioma volume is 360 
ml. Е. Intracerebral injection of ricin into tumor and peritumor 
area.  
Red arrows point to foci of dying glioma cells. Green arrows 
show the foci of dying normal nervous tissue cells. 
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approach that aims at the elimination of the CSCs is 
destined to fail. We should not go against nature and 
must not eliminate the CCs, but adapt to them and 
negotiate with the CSCs about their number and 
activity. Total elimination of the CCs and CSCs (by the 
methods of surgery, chemo and radiotherapy) will not 
arrest the unstoppable growth of malignant tumor, 
because the CCs and CSCs will evolve and adapt to 
new conditions.  
According to Prof. Alexander Archakov [7], a 
healthy person has up to 500 thousand (5х105) CCs 
that circulate in a body, in pre-cancer the number of the 
CCs is up to 1 billion (<109), while in cancer the 
number of the cells is over 1 billion (>109). Therefore, 
even a healthy person has some number of the CSCs 
by default, but they are rigidly controlled by natural anti-
cancer systems of a human body (regulatory cells of 
immune system and TSSCs). To an extent, at this 
angle the problem of cancer can be represented as the 
problem of the loss of control over reproductive effector 
functions of the physiological population of the CSCs 
and the uncontrollable growth of them and CCs, their 
progeny, capable of unlimited proliferation. The CCs 
and CSCs become uncontrollable only to usual growth-
regulating mechanisms, but remain sensitive to extra-
strong regulatory effects [54] or targeted effects [55, 
56]. 
Viewed at this angle, the problem of cancer therapy 
can be presented as the problem of regulation and 
management of the number of the CCs and CSCs. The 
patient would be able to live with certain amount of the 
CSCs and CCs (up to 1 or 1.5 trillion), if their specific 
functioning, proliferative potential, and reproductive 
effector functions of the CSCs will be regulated and 
controlled by contemporary regulatory therapeutic 
means. 
If we learn how to control the proliferative potential 
and number of the CCs and CSCs in the body, we 
would be able to transfer the disease from acute and 
fatal into chronic and non-lethal and considerably 
increase the survival rates. It can hardly be achieved 
by conventional pharmacological and therapeutic 
methods, as these cells are genetically modified, 
mutated somatic cells, and they are almost 
irresponsive to the standard signals of intercellular 
interaction. It is known that the CSCs respond to extra-
strong signaling intracellular effects [9] and targeted 
effect, and, consequently, there is the chance to 
regulate them with intact and well manageable cell 
systems of the SCs and progenitor cells with specific 
properties [57]. A new paradigm of cancer therapy can 
be the following: control of the admissible number of 
the CCs and CSCs in the body, their regulation and 
compensation of the functional state in order to transfer 
 
Cancer SC MGB U87 
 
Cancer SC MGB U251 
Figure 3: The scheme of overlapped genes in the charts of expression of 29 000 genes of a neural stem cell (NSC), stem cell of 
U87 glioblastoma line and U257 glioblastoma line and their complete transcriptome profiles of gene expression. 
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an acute fatal malignant process into chronic and non-
lethal, to increase the survival rates and improve life 
quality of the patients. 
We should refuse from the ideas of complete cure 
from cancer and malignant neoplasms, and solve the 
problem of regulation of the number of SCs and CSCs 
step by step. Hence, a basically new alternative 
stepwise paradigm of cancer and malignant tumors 
therapy is proposed. This methodological approach 
was termed the cytoregulatory therapy (CRT) in the 
complex therapy of the tumors [56] that should take its 
place along with cytostatic, cytotoxic and cytoreductive 
approaches (Figure 4). The approach was described in 
details in several monographs and manuscripts in 
Russian, patented in the Russian Federation and 
summed up in the chapter Proteome-Based Anti-Tumor 
Cell Therapy of the Topics in Anti-Cancer Research, 
Vol. 3 [50]. The concept of cancer and MBT treatment 
was presented in our article published in the Russian 
journal Kletochnaya Transplantatsiya i Tkanevaya 
Ingeneriya (Cell Transplantation and Tissue 
Engineering) [56] in 2010. The main idea of it is that we 
have to refuse from total elimination of the CCs and 
learn to control their number and their growth using 
autologous stem and progenitor cells with remodeled 
transcriptome profile.  
The proposed method is highly technological, 
science-driven, individually tailored, targeted, low 
invasive, safe, showing low adverse effects and easy in 
its clinical application.  
From the above said, we know that the clinical 
diagnostics of cancer is only possible when the number 
of the CCs exceeds 1 billion, i.e. the number of CCs > 
109 [7].  
All contemporary methods of treatment have their 
natural limitations as they have natural limits for 
elimination of certain number of the CCs (Figure 5). 
The relapse of cancer or malignant neoplasm 
testifies of the ineffectiveness of anti-cancer properties 
in the autologous immune competent cells (ICCs) of 
the patient and ineffectiveness of antic-cancer features 
of the HSCs and TSSCs. Hence, the restoration of 
natural anti-cancer properties of the ICCs, HSCs and 
TSSCs can be the main tool of a new paradigm of the 
tumor therapy that obligatorily includes the immune 
therapy and cytoregulation along with conventional 
methods.  
At the first stage of the research (2005-2010) in 
animal models of the tumors, we used the technology 
of chemical induction of cell proteome by the inductors 
of apoptosis (viscumin, ricin) to remodel the proteome 
of the HSCs and TSSCs and showed technical 
opportunity to use the CRT for malignant tumors [8, 
54]]. However, in practical experimental application of 
the CRT to the models of different tumors it became 
 
Figure 4: The role and place of post-genome (proteome and transcriptome) technologies in the complex therapy of malignant 
tumors of the brain.  
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obvious that the regulation of the CSCs and CCs must 
be extremely accurate and precise, and that the 
individual features, genomics, proteomics of the CCs 
and CSCs of specific tumors and SCs of the patient’s 
organism must be taken into account (Figure 2). 
Further, we mapped, catalogued and profiled the 
proteins of the CSC and HSCs, NSCs and MSSCs 
isolated from the patients with GBM, lung cancer and 
breast cancer, and established a small number of 
proteins that can become crucial in the regulation and 
management of the growth of the CCs, which, if 
affected by healthy SCs and PCs of the patient with 
individually remodeled transcriptome, can control their 
number and their reproductive functions (expansion, 
angiogenesis, proliferation, migration and other) [8, 53].  
Relying on contemporary concept of carcinogenesis 
of Peter Duisberg, who considers the carcinogenesis to 
be the form of speciation, we established that use of 
post-genome technologies in the analysis of the CCs 
and CSCs allows for finding an “Achilles heel” in their 
proteome, which is represented as the protein similarity 
matrix (SM) [8]. We detected a stable group of 
proteome targets for specific regulation of the CCs and 
CSCs by healthy SCs that have the same tissue-
specific proteins. For it, the PP of the healthy SCs can 
be remodeled by chemical induction, purposefully 
modifying their transcriptome with low-molecular 
substances, or affecting the key proteins by appropriate 
microRNA to activate or suppress the key proteins 
genes expression. We proposed several methods of 
individual remodeling of the CCs proteome (avoiding 
Agent Tumor Point of Application Mechanism Effect  Authors 
Tykerb Breast cancer Protein produced by HER2/neu gene  
Eliminates 
HER2/neu of 
CSC  
CSC percentage in 
tumour  
< from 11% to 5% in 
63% -recovery.  
Jenny Chang Baylor 
University December 
2007  
Gleevec 
Chronic 
myeloleucosis. 
Medulloblastoma 
BCR-ABL Signaling 
pathways  
Inhibits BCR-ABL 
CSC signaling 
pathways  
Blocks drugs 
targeting in CSC  
National Cancer 
Institute (USA) 2001  
Feverfew extract Acute myeloleucosis 
CSC of acute 
myeloleucosis  
Parthenolide 
content blocks 
key enzyme of 
CSC proliferation  
Induces suicide in 
acute myeloleucosis 
CSC not involving 
normal SC  
Сraig T.Jordan  
Monica Guzman, 
Rochester University  
Rapamycin Leucosis Pten gene  CSC genes  
Suppresses CSC 
growth and 
stimulates normal 
SC growth  
Sean Morrison  
Michigan University  
2007  
Cyclopamine from 
Veratrum 
californicum 
extract 
Prostate cancer  
Colon cancer 
Glioblastoma 
Wnt and Sonic 
hedgehog signaling 
pathways  
Inhibits Wnt and 
Sonic hedgehog 
signaling 
pathways  
Suppresses CSC 
proliferation  
Michael Din,2007  
National Cancer  
Institute  
Monoclonal 
antibodies to 
CD44 protein  
Myeloid leukemia 
CD44 Membrane 
marker  
of CSC  
Blocks CD44 
protein on CSC 
surface  
Immobilizes CSC 
blocking migration 
pathways of CSC to 
the niches.  
Princess Margaret 
Hospital in Toronto 
(Canada), 2007  
Monoclonal 
antibodies to 
CD133+ protein 
Colon cancer CSC membrane marker  
CD133+ Cells 
grow as tumor 
spheres  
Block stem factor of 
CSC  
John Dick et.al 2006 
(Canada)  
Ruggero De Maria et 
al., 2006  
(Italy)  
Adenoviral vector 
carrying interferon 
b gene 
Glioma Production of interferon b  
Locally create 
high level of 
interferon –b in 
glioma  
Antiproliferative and 
proapoptotic 
influence towards 
CSC  
Nacamizo A.et al., 
2005  
Figure 5: Anticancer therapies targeted at the cancer stem cells. 
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gene engineering) with consequent computer design of 
regulatory PP and biochemical remodeling in vivo and 
in vitro. The main stages of the technology are 
patented in the Russian Federation, the international 
PCT application are filed; they were presented at the 
international congresses and published in the journals 
[53, 56, 57].  
This new post-genome and transcriptome evidence 
has the potential to lead to the modification of the 
available “Standard and options…” with regards to new 
knowledge. At the first stage, the standard treatment of 
the MBT must include the following: 1. The optimal 
microneurosurgery of the tumor; 2. Pharmaceutical 
chemotherapy drugs of the different lines of 
chemotherapy that were selected in the sensitivity tests 
of the culture lines of the patient’s tumor cells; 3. 
Minimal cytostatic doses of ionizing radiation that were 
individually selected in cell cultures (the course dose is 
not more than 3 Gy); 4. After conventional treatments, 
every cancer patient should receive an obligatory 
course of immune therapy with well-known anti-cancer 
vaccines [41] and the preparations of CTLs; 5. The 
intrathecal transfusion of haploidentical HSCs of close 
relatives [58]. In the case of relapse, the consequent 
stages of the treatment should include all 
cytoreductive, cytostatic and cytotoxic approaches and 
end in the cytoregulatory personalized preparation with 
remodeled proteome [50].  
Hereby, we propose our version of a new treatment 
standard and set of the options for effective therapy of 
the MBT and metastases to the brain: 
The First Stage 
1. Optimal microsurgical removal of the brain 
tumour. 2. Morphological analysis of the tumour tissue. 
3. Culturing, standardization and cryopreservation of 
patient’s CC line (PCCL). 4. Isolation and separation of 
the SCs. 5. Production of individual anti-tumour 
vaccines. 6. Individual selection of chemotherapy drugs 
according to the sensitivity tests of the PCCL. 7. The 
test for radiosensitivity of the CCs culture and detection 
of the minimal dose of radiation. 8. Production of the 
individual preparation of the autologous cytotoxic 
lymphocytes. 9. Mobilization and harvest of the stem 
cells of the first degree relative. 9. Endoscopic isolation 
of the sample of the olfactory sheath and culturing of 
the neural SCs for GBM, or biopsy of the bone marrow 
and culturing of the MSCSs for the cancer metastases 
to the brain. 10. Comparative proteome mapping and 
profiling of the CSCs and NSCs or MSSCs. 11. Whole 
transcriptome profiling of the CSCs and NSCs or 
MSSCs genes. 12. Production of the personalized anti-
tumour cell preparation with specific regulatory anti-
reproductive features. 13. First line chemotherapy 
according to the sensitivity test. 14. First radiotherapy 
(5 Gy maximal total dose). 15. Immune therapy with 
dendritic vaccines. 16. Intrathecal transplantations of 
hematopoietic SCs. 
If no relapse, the oncological process is monitored 
every 3 to 6 months and the vaccine, immune 
modulators and intrathecal transfusions of HSCs are 
administered. The dose of the glucocorticoid hormones 
must be reduced to minimal.  
If the tumour relapses, the second stage of the 
therapy is started: 1. The tumour is removed, the 
pathomorphological test is repeated and the CCs of the 
MTB are cultured. 2. The second line of chemotherapy 
is chosen depending on the sensitivity test and 
administered. 3. The dose of radiotherapy is chosen 
depending on the sensitivity test and administered (2 or 
3 séances with the total dose not more than 5 or 6 Gy). 
4. The cytotoxic lymphocytes are administered. 5. The 
autologous HSCs are harvested and cryopreserved. 6. 
The proteomic and whole transcriptomic mapping of 
HSCs, NSCs and CSCs genes. 7. The comparative 
bioinformation analysis to rpoduce the personalized 
anti-cancer preparation of the HSCs. 8. Administration 
of the personalized anti-cancer cell preparation. 
If the tumour relapses, the third stage of therapy is 
started: 1. The stereotaxic radiosurgery (total radiation 
not more than 5 Gy) and radiotherapy of the tumour 
bed and neighbouring area. 2. The third line of 
chemotherapy that was previously chosen in the tests. 
3. Administration of the CTLs. 4. Intrathecal administra- 
tion of the personalized anti-cancer cell preparation.  
If the tumour relapses, the fourth stage of the 
therapy is started: 1. The stereotaxic focused 
ultrasound ablation. 2. Radiotherapy of the tumour bed 
and neighbouring area (2 or 3 séances with the total 
dose not more than 5 Gy). 3. The third and fourth lines 
of chemotherapy that were previously chosen in the 
tests. 4 Administration of the CTLs. 5. Intrathecal 
administration of the personalized anti-cancer cell 
preparation. 
The number of the therapeutic courses is not limited 
and depends on the number of relapses; the scope of 
chemotherapy must be minimal, not more than 2 lines 
at one stage; maximal dose of radiation must not 
exceed 5Gy at one stage. 
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CONCLUSION 
The proposed standard of the MBT therapy that 
involves the post-genome technologies implements a 
basically new methodological approach to the therapy 
of the tumors, which is underpinned by novel paradigm 
of cancer regulation based on the regulation of the 
number of the CCs, control and management of the 
tumor growth, administration of accurately measured 
toxic chemotherapy agents and radiation, personali- 
zation of the anti-tumor treatment. 
The approach can change the existing conventional 
ideology of the therapy of malignant tumors and 
transfer the methodology of complete elimination of 
cancer cells to the scientifically-driven platform of the 
production of anti-cancer cell agent that uses the 
advances of genome and post-genome technologies 
for the cytoregulatory therapy. The methodology of the 
cytoregulatory therapy in the standard of the MBT 
treatment, allows for the development of strict 
indications for all ionizing radiations, thus, considerably 
reducing such side effects as radiation necrosis and 
consequences of radiation disease. The uncontrolled 
and mortal neoplastic process will be turned into 
chronic and non-lethal disease that does not influence 
the life quality of the patient and only requires dynamic 
monitoring and repeated courses of already developed 
personalized cell therapy. 
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